Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/35363
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Grant L. | en |
dc.contributor.author | Allan M. | en |
dc.date.accessioned | 2021-05-14T11:56:43Z | en |
dc.date.available | 2021-05-14T11:56:43Z | en |
dc.date.copyright | 2020 | en |
dc.date.created | 20200525 | en |
dc.date.issued | 2020-05-25 | en |
dc.identifier.citation | Neurology and Therapy. 9 (1) (pp 85-92), 2020. Date of Publication: 01 Jun 2020. | en |
dc.identifier.issn | 2193-8253 | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/35363 | en |
dc.description.abstract | Introduction: The main objective of this study was to examine discontinuation rates associated with delayed-release dimethyl fumarate (DMF) when used for the treatment of relapsing multiple sclerosis (MS) in a real-world, clinical practice setting. Method(s): Data were collected retrospectively from charts of adult patients with relapsing-remitting MS treated at a single large institution in Australia, who completed at least 6 months of continuous therapy, either with DMF or another MS medication administered following DMF discontinuation. The primary endpoint was overall discontinuation rate. Secondary endpoints included discontinuation rate 6 months after initiation of DMF therapy; incidence of adverse events, particularly gastrointestinal events; discontinuation rate because of adverse events; and use of concomitant medications by patients during administration of DMF. Result(s): A total of 100 patients initially prescribed DMF between October 1, 2013 and June 30, 2014 were included in the analysis. The mean age of the patients was 43 years and 80% were female. The overall discontinuation rate was 13%, with 9% discontinuing because of gastrointestinal tolerability issues, within the first 6 months. Dose changes as a result of adverse events occurred in 15% of patients, and none of the adverse events reported were serious. Only one patient discontinued owing to lack of efficacy. Conclusion(s): This study, conducted shortly after the approval of DMF in Australia when first-hand clinical experience was still limited, demonstrated that DMF has an acceptable tolerability profile in the real-world setting that is similar to that demonstrated in clinical trials.Copyright © 2019, The Author(s). | en |
dc.language | English | en |
dc.language | en | en |
dc.publisher | Adis | en |
dc.relation.ispartof | Neurology and Therapy | en |
dc.subject.mesh | multiple sclerosis | - |
dc.subject.mesh | unspecified | - |
dc.subject.mesh | acetylsalicylic acid | - |
dc.subject.mesh | alemtuzumab | - |
dc.subject.mesh | antacid agent | - |
dc.subject.mesh | antidiarrheal agent | - |
dc.subject.mesh | antihistaminic agent | - |
dc.subject.mesh | beta1a interferon | - |
dc.subject.mesh | fingolimod | - |
dc.subject.mesh | fumaric acid dimethyl ester [Adverse Drug Reaction] | - |
dc.subject.mesh | fumaric acid dimethyl ester | - |
dc.subject.mesh | glatiramer | - |
dc.subject.mesh | interferon beta serine | - |
dc.subject.mesh | natalizumab | - |
dc.subject.mesh | proton pump inhibitor | - |
dc.subject.mesh | serotonin 3 antagonist | - |
dc.subject.mesh | teriflunomide | - |
dc.subject.mesh | abdominal pain | - |
dc.subject.mesh | disease duration | - |
dc.subject.mesh | drug efficacy | - |
dc.subject.mesh | drug safety | - |
dc.subject.mesh | drug withdrawal | - |
dc.subject.mesh | flushing | - |
dc.subject.mesh | gastrointestinal disease | - |
dc.subject.mesh | multiple sclerosis | - |
dc.title | A Retrospective Analysis of Real-World Discontinuation Rates with Delayed-Release Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis. | en |
dc.type | Article | en |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1007/s40120-019-00174-3 | - |
dc.publisher.place | United Kingdom | en |
dc.identifier.source | 2003874480 | en |
dc.identifier.institution | (Allan) Monash Health, Clayton, VIC 3168, Australia (Grant) Biogen, North Ryde, NSW 2066, Australia | en |
dc.description.address | M. Allan, Monash Health, Clayton, VIC 3168, Australia. E-mail: michelle.allan@monashhealth.org | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2020 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | Adverse events Delayed-release dimethyl fumarate Discontinuation Disease-modifying agents Multiple sclerosis Real world | en |
dc.identifier.authoremail | Allan M.; michelle.allan@monashhealth.org | en |
dc.description.grant | Organization: *Biogen* Organization No: 100005614 Country: United States | en |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Article | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.